CycloLab started as a spin-off of Sanofi-Aventis Chinoin Pharma (1990) Over 40-year experience in all fields of CD-technology.
CycloLab produce sulfobutylether beta-cyclodextrin (SBECD, Dexolve™) in multiple ton scale annually under cGMP conditions based on an FDA-approved Drug Master File and CTD Format Dossier
DexolveTM is used in commercialand development phases for over 20 APIs by dozens of clients.
CycloLab's business model is free from license, milestone- and royalty payments
Sulfobutyl-ether-β-cyclodextrin sodium salt is a water-soluble derivative of β-cyclodextrin synthesized via sulfobutylation. It serves as a critical solubilizing agent in pharmaceutical formulations. The compound features the CAS 146820-57-9 identifier and molecular formula C42H60O29S4Na4.
Strict adherence to pharmacopoeial purity standards (USP/EP) is mandatory for injectable use. Storage requires sealed containers at controlled room temperature to prevent moisture absorption. Handling necessitates personal protective equipment to avoid respiratory or dermal irritation during industrial processing.